Tissue Regenix Share Discussion Threads

[channel pirate] 11/10/2016 14:33

Based at the time of writing then from the last 20 trades none are showing as buys, but from a process of elimination then I would say 16 of them are BUYS and only 4 are sells. This is based on my "dummy" buys during this time. Nothing for "the big boys" to hoover up just before Results..........!!!

[rayrac] 11/10/2016 14:02

In auction. That's something.

[rayrac] 11/10/2016 07:54

One thing is for sure, running costs will be higher. Just hope income can meet some of it and that income and running costs will clash very soon?
As long as it all looks very promising, then I'll be happy.

[luminoso] 10/10/2016 17:14

Well price action tells us nothing ! Generally I expect results to disappoint when they have been preceded by a price rise, and surprise to the upside when preceded by a share price decline. So, we can expect results to be solid without inspiring us, then ?!!

[channel pirate] 10/10/2016 09:03

To top-up or not to top-up now, that is the question !!!!!!!!!!!!!!!!

[bamboo2] 10/10/2016 08:51

Results out Wednesday

We'll see if the wide range of estimates from management for Dermis are on target

Hoping for an update on the Ortho CE mark.

[rayrac] 06/10/2016 07:49

Good news at BTG this morning! I've got a strange feeling about where things are heading at some time in the future!

[bamboo2] 28/9/2016 07:08

Notice of Interim Results Wednesday 12 October

Leeds, 28 September 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today gives notice that it will announce its interim results for the six months ending 31 July 2016, on Wednesday 12(th) October.

[bamboo2] 23/9/2016 07:25

swiss, I agree. Given that the co has a broad range of treatments, and that there aren't that many pharmas that would want all of them, splitting the co into three divisions a while ago makes this quite plausible.

[swiss paul] 22/9/2016 21:21

so am surmising the Edison research report did not light fires under anyone. My initial thoughts are that this is a flag up saying come and buy us - we have products but we will not be in profit for another couple of years.

Anyone think anything else?

[bamboo2] 21/9/2016 02:14

LEEDS, England--(Business Wire)--Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”) will publish for the first time retrospective analysis on wound care product DermaPure® providing real world evidence of its use in clinical practice.

Retrospective Observational Analysis of the Use of an Architecturally Unique Dermal Regeneration Template (DermaPure®) for the Treatment of Hard-to-Heal Wounds by Kimmel, Howard, Gittleman, Haley, is now available online and will feature in the ‘International Wound Journal’, the first time a US physician has published a DermaPure® study in a peer reviewed journal.

The data which has been collated from 37 patients across 29 treatment centres, mainly focusses on the use of DermaPure® in the treatment of chronic wounds such as Diabetic Foot Ulcers (DFU) 37.8% and Venous Leg Ulcers (VLU’s) 18.9%, with the remaining patients being treated for either traumatic or surgical wounds.

At the time of application, the average wound size was 12.88cm2 and had been present for 56 weeks. The end point of the study was considered to be once complete closure was established, something which was achieved with one application of DermaPure in an average time of 10.58 weeks.

The retrospective data analysed proved to be consistent with what has been observed in published studies previously undertaken by NHSBT in the UK and showed complete healing for:

DFU’s - 52% at 4 weeks

73% at 8 weeks

85% at 12 weeks

Average time to heal 8.21 weeks

VLU’s - 49% at 4 weeks

70% at 8 weeks

81% at 12 weeks

Average time to heal 11.29 weeks

When compared with two other retrospective trials of acellular dermis used to treat DFUs DermaPure® was proven to heal more effectively with fewer applications.

Alongside this, a study undertaken at the University of Manchester looking into gene expression and the effect that this has on healing chronic wounds has been published in ‘Wound Repair and Regeneration’.

The findings of this research, led by Dr. Ardeshir Bayat, is of particular importance as optimal wound healing is dependent upon appropriate gene expression. The outcome of this study has confirmed that by applying DermaPure® to a chronic wound, such as a DFU, post debridement, the wound is converted to an acute wound, allowing the body to progress naturally through the wound healing cycle. Chronic wounds that did not receive this treatment had different gene expression and remained unable to advance appropriately through the healing process. Thus, proving a treatment such as DermaPure® to have a significant advantage when treating patients suffering with chronic wounds, such as DFU’s, where the amputation rate can be as high as 15%.

Greg Bila, President, Tissue Regenix Wound Care Inc. said: “The publication of this clinical data is key in highlighting the problems physicians face when treating chronic wounds, and how regenerative treatments such as DermaPure® address, and potentially revolutionize, the outlook for these patients. Many times products illustrate outcomes in the study environment that are seldom seen in the real world clinical environment. However, we now have two substantive pieces of research that illustrate the effectiveness of Tissue Regenix dCELL® Technology in the treatment of chronic and acute wounds, and demonstrates the potential effectiveness of this technology in other areas of healthcare.”

A full copy of the peer reviewed paper is available here,

[rayrac] 17/9/2016 14:30

Quite why we have this thread I do not know! Some threads overdo it one way, but this one certainly under-does it by a mile.👉ӿ99;😡

[rayrac] 16/9/2016 11:57

Becoming of some interest! The Edison report has some effect. Give it time!

[bamboo2] 10/9/2016 14:25

A sad story of failed regenerative medicine.

"In July 2011, the world was told about a sensational medical breakthrough that had taken place in Stockholm, Sweden. The Italian surgeon Paolo Macchiarini had performed the world's first synthetic organ transplant, replacing a patient's trachea, or windpipe, with a plastic tube.

But some of his academic research is now seen as misleading, and most of the patients who received his revolutionary treatment have died. What went wrong?"

[loldemort] 07/9/2016 14:36

No, I'm just saying that it's swings and roundabouts. For a co that has both its revenues *and* its costs abroad, I don't particularly care about the exchange rate.

[bamboo2] 07/9/2016 08:41

Loldemort, is a currency headwind a major comcern at this point?
On target income figures for the first full trading year must surely be the priority?
We will see in October.

[loldemort] 06/9/2016 20:57

In the meantime, of course, the fall in the pound will also increase costs when expressed in Sterling.

[channel pirate] 26/8/2016 09:39

So a big trade at mid price this morning - 4,679,467 shares costing £959,290 - not me honestly (ha-ha)

[luminoso] 23/8/2016 16:46

Why not indeed !

[rayrac] 17/8/2016 19:09

Still long...and why not!

[andrewbaker] 17/8/2016 15:35

It looks like there is interest in TRX, given the jump today, and also in the past when the price has faded. Given the fall in the £, and the fact most sales are in US$s or other foreign currencies, this will improve the financial returns, even without increased sales; which themselves are happening, and will continue so to do. Still long, and still very happy. :)

[bamboo2] 17/8/2016 11:53

I am thinking that the recent flurry of reports/vids etc is designed to help find a partner. There are a couple of large pharmas I know of, that may be a good fit, if a deal can be struck.

[bamboo2] 17/8/2016 08:26

dCELL Technology - CardioPure

Published on Aug 4, 2016

Travel to Curitiba, Brazil to see how Tissue Regenix unique dCELL® technology is transforming the lives of heart valve patients. With over 1,600 operations now undertaken, hear from both the patients who have received the dCELL® valves and Dr Francisco da Costa who is pioneering the treatment in Curitiba, where dCELL® valves have now set the benchmark for treatment.[68views]